WAG

2022 was a dreadful year for investors with the S&P 500 down almost 20% and the Nasdaq lower by a stunning 33%, and what a difference a year can make. Through Tuesday morning the S&P 500 was up...
When pending mergers take too long to close due to regulatory reviews, it is not unusual for investors to get burned.
It is not that often that one company gets two huge thumbs-up from analysts in the same week when there is not an earnings report. That is the case for Walgreens Boots Alliance.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Boston Scientific, Micron Technology, Salesforce.com, TransCanada and Walgreens Boots Alliance.
Walgreens Boots Alliance Inc. (NASDAQ: WBA) is the world’s largest drug store chain and promises to grow even larger if its proposed merger with Rite Aid Inc. (NYSE: RAD) is completed....
Credit Suisse started new analyst coverage on many health care related stocks on Wednesday, issuing very positive views on Rite Aid and on would-be acquirer Walgreens Boots Alliance.
The Wall Street Journal and Dow Jones have reported that Walgreens Boots Alliance is nearing a deal to acquire Rite Aid.
Since the start of July, there have been five key U.S. dividend hikes that were simply too large or too important to ignore.
Retailers are announcing December U.S. same-store sales figures Thursday. Retail Metrics projected an overall gain of 3.8%.
Walgreen reported better-than-expected first-quarter fiscal 2015 results before markets opened Tuesday morning.
Wednesday's top analyst upgrades and downgrades from 24/7 Wall St. include BP, CSX, Dollar General, EMC, Sprint, 3D Systems and Disney.
Source: courtesy of Wal-Mart StoresIt’s a marketing adage that keeping an existing customer is both cheaper and easier than wooing a new one. It takes time and money to become one of America’s...
Retail Metrics attributes the rather lackluster October U.S. same-store sales to unseasonably warm weather and “uninspiring fashion.”
Nothing like the biggest market sell-off in years to get insiders' taste buds warmed up to do some buying.
Diplomat Pharmacy priced its IPO shares at $13 on Thursday, but when the stock began trading Friday morning it opened at $16.